Regeneron Pharmaceuticals Inc

REGNNASDAQ • USD
ThemeBiotech - Drug Development›Immunology & Autoimmune
834.04 USD
↗ 7.40 (0.90%)AT CLOSE (11:59 AM EDT)
837.50
↗ 3.46 (0.42%)
POST MARKET (AS OF 07:59 PM EDT)
Post Market
AS OF 07:59 PM EDT
837.50
↗ 3.46 (0.42%)
🔴Market: CLOSED

Regeneron Pharmaceuticals Inc (REGN) trades at $834.04 per share. Technical and fundamental signals align bullish — technicals rate "Strong Buy" while fundamentals indicate "Buy". Key drivers include a robust Altman Z-Score and a bearish Death Cross on the long-term moving averages. REGN is fairly valued relative to its sector peers based on current multiples.

Technical & fundamental data as of Aug 21, 2026.

Open?$835.74
High?$847.00
Low?$826.64
Prev. Close?$826.64
Volume?786.9K
Avg. Volume?773.6K
VWAP?$835.17
Rel. Volume?1.02x
Bid / Ask
Bid?$831.20 × 40
Ask?$845.00 × 40
Spread?$13.80
Midpoint?$838.10
Valuation & Ratios
Market Cap?85.9B
Shares Out?101.1M
Float?97.5M
Float %?94.6%
P/E Ratio?19.84
P/B Ratio?2.71
EPS?$42.04
Dividend?0.44%
Ex-Dividend?N/A
News
Profile
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
Themes
Biotech - Drug Development›Immunology & AutoimmuneHealthcare - Oncology›Immunotherapy & Immuno-OncologyHealthcare - Genomics & Precision Medicine›Gene Therapy & Gene Editing
Employees
15.4K
Market Cap
85.1B
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.regeneron.com
Listed
1991-04-02
Address
777 OLD SAW MILL RIVER ROAD
TARRYTOWN, NY 10591
Phone: (914) 847-7000
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+1/3)
Medium-Term (Wave)?▲ Bullish(+3/3)
Short-Term (Ripple)?– Neutral(0/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookBuy
Strong SellNeutralStrong Buy
F-Score?
60
Z-Score?
100
Momentum?
48
Short Sent.?
69
Piotroski F-Score?5/9Mixed
Altman Z-Score?7.45Safe
Confidence?69%Moderate
Full Fundamental Analysis →
Short InterestModerate
Short % of Float?3.47%Low
Short Interest?3.4M
Days to Cover?3.9
Free Float97.5M
Avg Daily Volume858.7K
Settlement Date2026-07-31
Financial Health
Current Ratio?3.34Strong
Quick Ratio?2.78Strong
Cash Ratio?0.44Low
Debt/Equity?0.09Low
ValuationFAIRLY VALUEDvs 10 peers + S&P 500
Score
72/100
P/E?
Peers
100
S&P
65
19.8FAIR▾
P/B?
Peers
70
S&P
60
2.71CHEAP▾
P/S?
Peers
82
S&P
25
5.53FAIR▾
P/FCF?
Peers
75
S&P
46
22.8FAIR▾
EV/EBITDA?
Peers
63
S&P
27
19.7FAIR▾
EV/Sales?
Peers
82
S&P
32
5.54FAIR▾
Returns & Efficiency
ROE?
Peers
50
S&P
50
13.7%STRONG▾
ROA?
Peers
71
S&P
75
10.4%STRONG▾
Cash Flow & Enterprise
FCF?$3.8B
Enterprise Value?$86.1B
Fundamentals ratios updated end of day
MarketsMoversWatchlist